Division of Hematology and Oncology Archive — Page 6 of 15

Pregnant woman holding pill pack
August 2, 2022

Targeted cancer drug during pregnancy

The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.

By Leigh MacMillan
July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

By Tom Wilemon
June 16, 2022

Breast cancer biomarkers of response

Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.

By Joshua Baker
May 26, 2022

Conquer Cancer awards given to five hematology-oncology fellows

Five Vanderbilt University Medical Center hematology and oncology fellows will receive awards from Conquer Cancer, the ASCO Foundation, during the 2022 American Society of Clinical Oncology Annual Meeting in Chicago, June 3-7.

By Tom Wilemon
May 6, 2022

Janet Darnell received a lifesaving lung transplant. Five months later she received lifesaving surgery for colon cancer. She calls herself a “walking miracle.”

Without the lung transplant, the cancer may never have been detected.

By Matt Batcheldor
April 25, 2022

Molecular testing across tumor types

The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

By Leigh MacMillan